RECOMBINANT ERYTHROPOIETIN MARKET ANALYSIS

Market News

Recent Developments

New product launches/ approval

• In July 2019, Kyowa Kirin Co., Ltd., a company involved in the discovery, development, production, and commercialization of pharmaceuticals and biotechnology products, announced the launch of the "Darbepoetin Alfa Injection Syringe [KKF]" in Japan.
• In September 2019, JCR Pharmaceuticals Co., Ltd., a pharmaceutical company, announced that they had received marketing approval in Japan for Darbepoetin Alfa BS Injection JCR, a long-acting erythropoiesis-stimulating agent.

Collaboration and partnerships

• In September 2020, Lotus Pharmaceutical Co., Ltd, which manufactures and distributes oral medicine, ointment, and injection medicine, announced a partnership with Chong Kun Dang Pharmaceutical Corp, a company engaged in the manufacture, distribution, research, and development of pharmaceuticals, for the biosimilar Darbepoetin alfa, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure. This long-term partnership will provide Lotus Pharmaceutical Co., Ltd. the rights to market the Darbepoetin alfa exclusively in Taiwan and South East Asian markets.
• In October 2020, Astellas Pharma Inc., a pharmaceutical company, announced that, in collaboration with FibroGen, a biopharmaceutical company, and AstraZeneca, a global pharmaceutical company, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined Congress. Six abstracts (one oral presentation and five ePosters) sponsored by Astellas focus on the use of roxadustat as a treatment in adult patients with anemia of chronic kidney disease (CKD). These abstracts include presentations of the Phase 3 DOLOMITES study (abstract #TH-OR02) and a Japanese Phase 3 CL-0310 study (#PO0269), with both studies evaluating roxadustat versus darbepoetin alfa as a treatment for patients with anemia of CKD not on dialysis. Other presentations include safety data from two Japanese Phase 3 studies assessing the ophthalmological effects of roxadustat treatment in patients with anemia of CKD on dialysis and not on dialysis, and a study of patients' treatment preferences for anemia of CKD.